2022
DOI: 10.1093/ofid/ofac492.1594
|View full text |Cite
|
Sign up to set email alerts
|

1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico

Abstract: Background Cancer patients (CPs) with COVID-19 have an increased risk of adverse outcomes. In addition, CPs seem to have a lower immune response to SARS-CoV-2 vaccination. This study aimed to evaluate SARS-CoV-2 spike antibodies (anti-S Abs) following COVID-19 vaccination in CPs and healthcare workers (HCWs). Methods We conducted a point-seroprevalence study in CPs and HCWs who received a two-dose scheme with either BNT162b2,… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles